Publications on NCI-60 Screen

1. Su G, Burant CF, Beecher CW, Athey BD, Meng F. Integrated metabolome and transriptome analysis of the NCI60 dataset. BMC Bioinformatics 2011; 12 (suppl 1): S36.
2. Sokilde R, Kaczkowski B, Podolska A, Cirera S, Gorodkin J, Moller S, Litman T. Global microRNA analysis of the NCI-60 cancer cell panel. Molec Cancer Therap 2011; 10: 375-84.
3. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Lee JS, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell lines set. Molec Cancer Therap 2010; 9: 257-67.
4. Covell DG, Huang R, Wallqvist A. Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Molec Cancer Therap 2007; 6: 2261-70.
5. Shoemaker RH. The NCI60 human tumor cell line anticancer drug screen. Nature Rev Cancer 2006; 6: 813-23.
6. Phillips LR, Hill KD, Majerova E. Liquid chromatographic determination of NSC 737664 (ABT-888: an inhibitor of poly(ADP-ribose) polymerase (PARP)) in plasma and urine in a phase 0 clinical trial. J Liq Chromatogr Relat Technol 2009; 32: 261-72.
7. Boyd, M.R., and Paull, K.D. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Development Research 34: 91-109, 1995.
8. Grever, M.R., Schepartz, S.A., and Chabner, B.A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Seminars in Oncology, Vol. 19, No. 6, pp 622-638, 1992.
9. Alley, M.C., Scudiero, D.A., Monks, P.A., Hursey, M. L., Czerwinski, M.J., Fine, D.L., Abbott, B.J., Mayo, J.G., Shoemaker, R.H., and Boyd, M.R. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Research 48: 589-601, 1988.